Нейробластома у детей.
Клинико-эпидемиологическое исследование
Диссертация
Нейробластома в настоящее время остается «проблемной» опухолью в детской онкологии. Она является наиболее частой экстракраниальной солидной опухолью, ее биологическое поведение непредсказуемо ' (спонтанная регрессия, созревание в ганглионеврому, склонность к агрессивному развитию), и мало, что известно о большинстве факторов риска, которые участвуют в этиопатогенезе, а также сложность выявления… Читать ещё >
Содержание
- ВВЕДЕНИЕ
- ГЛАВА 1. Обзор литературы
- 1. 1. Эпидемиология, этиология и биология нейробломы
- 1. 2. Клиника, диагника, рининг нейробломы
- 1. 3. Клификация и критерии групп ра
- ГЛАВА 2. Материалы и методы ледования
- ГЛАВА 3. Ретроспективное исследование нейробластомы по данным клиники НИИ ДОГ за 1990−2008 гг
- 3. 1. Характерика пациентовнейробломой по овным прогничим факторам (по полу, возру, адии и другим)
- 3. 2. Алгоритм диагностического обследования больных с нейробломой и оценка эффективни лечения
- ГЛАВА 4. Популяционное ледование нейробломы в г. Мве
- 4. 1. Демографическая характеристика детского населения г. Мвы
- 4. 2. Популяционные характеристики нейробластомы у детей в г. Москве по полу, возру, адии, локализации и му лечения)
- 4. 3. Заболеваемость и смертность детей с нейробластомой в г. Мве
- 4. 4. Временные и территориальные вариации заболеваемости нейробломой в г. Мве
- 4. 5. Оценка эффективности лечения нейробластомы у детей в г. Мве
- 4. 6. Сравнительный анализ показателей заболеваемости, смертности и выживаеми детейнейробломой в г. Мве и в Германии
- ОБСУЖДЕНИЕ
Список литературы
- Аксель Е.М., Давыдов М. И., Ушакова Т. Н. Злокачественные новообразования желудочно-кишечного тракта: основные статистические показатели и тенденции //Современная онкология. 2001.- Т. 3, № 4. -С. 10−22.
- Алиев М.Д., Поляков В. Г. Злокачественные опухоли у детей. В кн.: Онкология. Национальное руководство./ Под редакцией В. И. Чиссова, М. И. Давыдова, — М.:Гэотар-Медиа, 2008.- С.956−962.
- Бондарь И.В., Мень Т. Х. Злокачественные новообразования у детей в России/ЛУ съезд онкологов и радиологов СНГ: избранные лекции и доклады.-Баку-, 2006-С. 337−340.
- Бояршинов В.К. Лечение нейробластомы IV стадии: Автореф. Дис. .канд. мед. наук.- М., — 2001- С.9−19.
- Варфоломеева С.Р. Клинико-эпидемиологический и терапевтический контроль злокачественных новообразований у детей и подростков. Автореф. Дис.. .доктора мед. наук. М., -2008
- Дурнов Л А. Руководство по детской онкологии// -М.: Миклош, 2003.-С. 361−376.
- Мень Т.Х., И.В. Бондарь, Ю. С. Федякова Смертность детей от злокачественных опухолей в России// Вопросы онкологии, -2007. Т.53, № 5.-С. 510−514.
- Панферова Т.Р., Кошечкина Н. А., Волкова Л. Д. и др. Эхогафия в оценке эффективности лечения забрюшинной нейробластомы у детей// Диагностическая и интервенционная диагностика в педиатрии: материалы II межд. симпозиума.- М., 1999.- С. 22.
- Черствой Е.Д., Г.И. Кравцова, А. В. Фурманчук Опухоли симпатической нервной системы. В кн.: Опухоли и опухолеподобные процессы у детей // Минск: Аскар, -2002. С.125−137.
- Шориков Е.В., Т.П. Попова, О. В. Лемешева, Е. Р. Семенихина, Г. А. Цаур, Л. И. Савельев, Фечина Л. Г. Ретроспективный анализ эффективностипрограммного лечения пациентов с нейробластоммой// Детская онкология, -2008.- № 2 С. 83−88.
- AIRT Working Group/ Italian cancer figures- report 2006: Incidence, mortality and estimates.// Epidemiol Prev -2006- № 30 P. 8−10, 12−28.
- Ajiki W., Tsukuma H., Oshima A., Kawa K. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan// Cancer Causes & Control -1998/ -Vol. 9, No. 6. P. 631−636.
- Altmann AE, Halliday JL, Giles GG. Associations between congenital malformations and childhood cancer. A register-based case-control study.// Br J Cancer -1998/.- Vol.78.- P. 1244−1249.
- Ambros PF, Brodeur GM. Concept of tumorigenesis and regression. In: Neuroblastoma//—Brodeur GM, Sawada T, Tsuchida Y, Voute PA, eds. Amsterdam: Elsevier. -2000. P. 21−29.
- American Joint Committee on Cancer. Neuroblastoma. Manual for Staging of Cancer// Philadelphia: J.B. Lippincott -1983. No 2. P- 237.
- Attiyeh EF, London WB, Mosse YP, et al. Chromosome lp and 1 lq deletions and outcome in neuroblastoma.// N Engl J Med -2005.- Vol. 353, No 21. P. 2243−2253.
- Auber F, Larroquet M, Bonnard A, Boudjemaa S, Landman-Parker J, Ducou Le Pointe H, Boccon-Gibod L, Lefebvre G, Uzan S, Helardot P, Audry G. Prenatal ultrasound diagnosis of neuroblastoma.// Gynecol Obstet Fertil. 2005.- Vol. 33, No4. — p: 228 -231.
- Baker DL, Schmidt M, Cohn S, et al. A phase III trial of biologically-based therapy reduction for intermediate risk neuroblastoma.// J Clin Oncol 2007.- Vol. 25, Nol8: A-9504.
- Berthold F, Trechow R, Utsch S, et al. Prognostic factors in metastatic neuroblastoma: a multivariate analysis of 182 cases.// American Journal of Pediatric Hematology/Oncology 1992.- Vol. 14, No 3. — P. 207−215.
- Bourhis J, DeVathaire F, Wilson GD, et al. Combined analysis of DNA ploidy index and N- myc genomic content in neuroblastoma.// Cancer Res 1991. -Vol. 51.-P. 33−36.
- Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.// N Engl J Med 1999. — Vol. 340, No 25.-P. 1954−1961.
- Brodeur GM, Castleberry RP. Neuroblastoma. // In: Pizzo PA, Poplack DG. B. //Principles and practice of pediatric oncology, 3rd ed. 1997- P. 761−797.
- Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.// J Clin Oncol. 1993. — Vol. 11, No8. — P. 1466−1477.
- Brodeur GM and Maris JM, Neuroblastoma. In: Pizzo PA and Poplack DG, Editors, Principles and practice of pediatric oncology (5th edn.)// J В Lippincott Company, Philadelphia -2006. P. 933−970.
- Brodeur GM, Azar C, Brother M, et al. Neuroblastoma. Effect of genetic factors on prognosis and treatment.// Cancer 1992.- Vol. 70, No 6. — P. 16 851 694.
- Brodeur GM, Maris JM, Yamashiro DJ, et al. Biology and Genetics of Human Neuroblastomas.// J Pediatr Hematol Oncol 1997. — Vol. 19, No 2. — P. 93−101.
- Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N- myc in untreated human neuroblastomas correlates with advanced disease stage.// Science 1984. — Vol. 224. — P. 1121−1124.
- Brodeur GM Clinical and biological aspects of neuroblastoma, in Vogelstein B, Kinzler KW (eds): The Genetic Basis of Human Cancer. // New York, NY, McGraw-Hill 1998. — P. 691−711.
- Brodeur GM, Seeger RC, Barrett A, et al International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma //
- J. Clin. Oncol.- 1988.- Vol. 6, No 12 .-P. 1874−1881.
- Buck GM, Michalek AM, Chen CJ, et al. Perinatal factors and risk of neuroblastoma.// Paediatr Perinat Epidemiol 2001.- Vol. 15, P. 47−53.
- Carlsen NL. Neuroblastomas presenting in the first year of life: epidemiological differences from those presenting at older ages. // Cancer Detect Prev -1996- Vol. 20.- P. 251−261.
- Caron H, van Sluis P et al. Allelic loss of chromosome lp as a predictor of unfavorable outcome in patients with neuroblastoma. // N Engl J Med. 1996. — Vol.334, No 4.-P. 225−230.
- Caron H, Peter M, van Sluis P, et al. Evidence for two tumor suppressor loci on chromosomal bands lp35−36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification.// Hum Mol Genet -1995.-Vol. 4. P. 535−539.
- Castleberry R.P., Shuster J.J., Smith E. I. The Paediatric Oncology Group experience with the International Staging System criteria for neuroblastoma. //
- J. Clin. Oncol. 1994. — Vol. 12 P. 2378−2381.
- Castleberry R. P. Biology and treatment of neuroblastoma. //Pediatr Clin North Am -1997. -Vol. 44. P. 919−938.
- Chamberlain J, Moss S., et al. Evaluation of Cancer Screening. // London: Springer, -1996. P.145−149.
- Chauvin F, Mathieu P, Frappaz D, et al. Screening for neuroblastoma in France: methodological aspects and preliminary observations.// Medical and Pediatric Oncology -1997. Vol. 28, No2. -P.81−91.
- Cheung N.K., Kushner B. V., et al. Reducing Therapy for Low-risk and Advancing Immunotherapy for High-risk Neuroblastoma.// http://www.asco.org/ASCO/2007
- Cheung N.K., Kushner В .V., Cheung I.Y., et al. Anti -G (D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. // J Clin Oncol -1998. Vol. 16, No 9. — P. 3053−3060
- Citak С, Karadeniz С, Dalgic В, et al. Intestinal lymphangiectasia as a first manifestation of neuroblastoma.// Pediatr Blood Cancer -2006. Vol.46, No 1. -P. 105−107.
- Cohn SL., Pearson A.- London W.B., et al. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report// Journal of Clinical Oncology -2009. Vol. 27, No 2. — P. 289−297.
- Connolly AM, Pestronk A, Mehta S, et al. Serum autoantibodies in childhood opsoclonus-myoclonus syndrome: an analysis of antigenic targets in neural tissues.// J Pediatr 1997. — Vol. 130, No 6. — P. 878−884.
- Conte M, Parodi S, De Bernardi B, Milanaccio C, et al. Neuroblastoma in adolescents: the Italian experience.// Cancer. -2006. Vol. 106 No 6. — P. 14 091 417.
- DeBaun M .R., Tucker M. A. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrom. // J. Pediatr 1998.-Vol. 132, No 3, Ptl.-P. 398−400.
- De Bernardi B, Pianca C, Pistamiglio P, et al. Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases.// J Clin Oncol -2001.- Vol. 19. P. 183−190.
- De Bernardi B, Balwierz W, Bejent J, et al. Epidural compression In neuroblastoma: Diagnostic and therapeutic aspects. // Cancer Lett 2005. — Vol. 228. -P.283−299.
- Dubois S.G., Kalika Y., Lukens J.N., et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.// J Pediatr Hematol Oncol. -1999.-Vol. 21.-P. 181−189.
- Evans A.E., D ' Angio G.J., Randolph J.A. A proposed staging for children with neuroblastoma. Children’s cancer study group A. // Cancer -1971. Vol. 27. — P. 374−378.
- Eds PA Voute et al. Cancer in Children: Clinical Management (5th ed).// Oxford University Pressio — 2005-.
- Ferris I., Tortajada J, Ortege Garcia JA, et al. Risk factors for neuroblastoma // An Pediatr (Bare) 2005. — Vol. 63, No 1. — P. 50−60.
- Ferguson WS, Forman EN. Childhood cancer: past successes, future directions. // Med Health RI 2002. — Vol. 85. — P. 17−22.
- Franks LM, Bollen A, Seeger RC, et al. Neuroblastoma in adults and adolescents: an indolent course with poor survival.// Cancer -1997. Vol. 79, No 10.-P. 2028−2035.
- Gao R.N., Levy I.G., Woods W.G., Coombs B.A., Gaudette L.A., Hill G.B. Incidence and mortality of neuroblastoma in Canada compared with other childhood cancers.// Cancer Causes Control. 1997. — Vol.5. — P. 745−754.
- Gatta G, Zigon G, Capocaccia R., and all., and the EUROCARE Working Group Survival of European children and young adults with cancer diagnosed 1995−2002 // Eur J Cancer. 2009. — Vol. 45, No 6. — P. 992−1005.
- George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.// J Clin Oncol -2005. Vol. 23. — P. 6466−6473.
- George RE, Lipshultz SE, Lipsitz SR, et al. Association between congenital cardiovascular malformations and neuroblastoma.// J Pediatr 2004- 144: 444−448.
- George RE, Li S, Medeiros-Nancairow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.// J Clin Oncol. -2006.- vol. 24, Nol8. -P.2891−2896.
- German Childhood Cancer Registry. Report 2008.
- Goodman M. T, Gurney J. G, Smith M. A, Olshan A.F. National Cancer Institute, Surveillance, epidemiology and End Results Database. http://seer.cancer.gov (2005)
- Grosfeld JL. Neuroblastoma. In: O’Neill JA, Rowe MI, Grosfeld JL, et al //ds. Pediatric Surgery. 5th ed. St Louis: CV Mosby. -1998. P. 405−419.
- Guglielmi M, De Bernardi B, Rizzo A, et al. Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course?// J Clin Oncol -1996. Vol.14, No5. -P. 153 7−1544.
- Gurney JG, Severson RK, Davis S, et al. Incidence of cancer in children in the United States: sex-, race-, and 1-year age-specific rates by histologic type.// Cancer.-1995.-vol. 75, No8.-P. 2186−2195 .
- Gurney JG- Ross JA- Wall DA- Bleyer WA- Severson RK- Robison LL Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992.// J Pediatr Hematol Oncol 1997. — vol.19, — P.5428−5432.
- Gutierrez J., Fischer A., Sola J., et al. Markedly improving survival of neuroblastoma: a 30-year analysis of 1,646 patients // Pediatric Surgery International -2007. vol. 23, No7. — P. 637−646.
- Haber M, Smith J, Bordow SB, et al. Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.// J Clin Oncol -2006. vol. 24, No 10. — P. 1546−1553.
- Hamrick SE, Olshan AF, Neglia JP, et al. Association of pregnancy history and birth characteristics with neuroblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group.// Paediatr Perinat Epidemiol -2001- vol. 15.-P. 328−337.
- Hann HW, Evans AE, Siegel SE, et al.: Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: the Childrens Cancer Study Group experience.// Cancer Research -1985.- vol. 45, No 6. -P. 2843−2848.
- Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. The epidemiology of neuroblastoma: a review.// Paediatr Perinat Epidemiol.- 2009. — vol.23, No 2. P. 125−143.
- Hiyama E, Hiyama K, Nishiyama M, Reynolds CP. et al. Differential gene expression profiles between neuroblastomas with high telomerase activity and low telomerase activity, J Pediatr Surg 2003- 38: 1730−4
- Hiyama E, Reynolds CP Telomerase as a biological and prognostic marker in neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y Neuroblastoma. //New York, NY: Elsevier Science, 2000- 159−174.
- Hiyama E, Yokoyama T, Hiyama K, et al. Multifocal neuroblastoma: biologic behavior and surgical aspects. //Cancer 2000- 88 (8): 1955−63,
- Hiyama E, Lehura T, Sugimoto T, Fukuzawa M, et al. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.// Lancet -2008- 371(9636): 1173−80
- Holgersen LO, Subramanian S, Kirpekar M, et al. Spontaneous resolution of antenatally diagnosed adrenal masses.// J Pediatr Surg 1996- 31 (1): 153−5.
- Honjo S., Doran H.E., Stiller C.A., Ajiki W., Tsukuma H. Neuroblastoma trends in Osaka, Japan, and Great Britain 1970−1994, in relation to screening.//J Cancer -2003 Feb 10−103(4):538−43.
- Howman-Giles R, Shaw PJ, Uren RF, Chung DK Neuroblastoma and other neuroendocrine tumors//. SeminNucl Med 2007- 37 (4): 286−302.
- Hsu LL, Evans AE, D’Angio GJ Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate.// Med Pediatr Oncol -1996.- 27 (6): 521−8.
- Jennings RW, LaQuaglia MP, Leong К, Hendren WH, Adzick NS. Fetal neuroblastoma: prenatal diagnosis and natural history.// J Pediatr Surg. -1993. -vol. 28, No 9.- P. 1168−1174.
- Johnson C.C., Spitz M.R. Neuroblastoma: case-control analysis of birth characteristics.// J Natl Cancer Inst -1985. vol. 74. — P.789−792.
- Kato K., Kato Y, at al. Ewing’s sarcoma family of tumor arising in the adrenal gland—Possible diagnostic pitfall in pediatric pathology: Histologic, immunohistochemical, ultrastructural, and molecular study. // Hum Pathol -2001.-vol. 32. P.1012−1016.
- Kemshead JT, Goldman A, Fritschy J, et al. Use of panels of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders.// Lancet -1983. vol.1. — P. 12−15.
- Клш N.W. Clinical implications of telomerase in cancer. // Eur J Cancer -1997.-vol. 33.-P. 781−786.
- Kitanaka C, Kato K, Ijiri R, et al.: Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression.// J Natl Cancer Inst -2002.- vol. 94, No 5. P. 358 368.
- Kramorova E., Stiller C.A. The international classification of childhood cancer// Int J. Cancer -1996. vol. 68 .- P. 759−765.
- Kushner В. H., and Cheung Nai-Kong V. Neuroblastoma — from Genetic Profiles to Clinical Challenge.// The new England J. of Medicine -2005. vol. 21, No 353.-P. 2215−2217
- Kushner B. H, Kramer K, LaQuaglia M.P., et al. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. //Med Pediatr Oncol- 2003. vol. 41, No 6. P. 508−515.
- Kushner B.H., Cheung N.K. Exploiting the MIBG-avidity of neuroblastoma for staging and treatment.// J Pediatr Blood Cancer -2006. vol. 47. P. 863−864.
- Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.// Journal of Clinical Oncology- 1991.- Vol. 9, No4. -P. 581−591.
- Mahoney NR, Liu GT, Menacker SJ, et al. Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions.// Am J Ophthalmol -2006.- Vol. 142, № 4. -P. 651−659.
- Maris JM, Hogarty MD, Bagatell R, Cohn SL). Neuroblastoma. //Lancet -2007.- vol. 369 No 9579. -P. 2106−2120.
- Maris J.M., Matthay K.K. Molecular biology of neuroblastoma.// J Clin Oncol. -1999 17(7) -P. 2264−2279.
- Maris JM, Chatten J, Meadows AT, Biegel JA, Brodeur GM. Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease.// Med Pediatr Oncol -1997. vol. 28. -P. 1−5.
- Maris J. M, Woods W. G. Screening for neuroblastoma: a resurrected idea?// Lancet -2008.-vol. 371, No 9619 .-P. 1142−1143.
- Massaron S, Seregni E, Luksch R, et al. Neuron-specific enolase evaluation in patients with neuroblastoma.// Tumor Biology -1998. vol.19, No 4- P. 261 268.
- Matthay K.K., Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004.// Cancer Lett -2005. -Vol. 228 (1−2). P. 275−282.
- Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study.// J Clin Oncol -1998.- vol.16, No 4. P. 1256−1264
- McCall EE, et al. Maternal hair dye use and risk of neuroblastoma in offspring Cancer Causes and Control 2005.- vol.16, No 6.- P.743−748.
- Menegaux F, et al. Day Care, Childhood Infections and Risk of Neuroblastoma// Am J Epidemiol-2004.-vol. 159.-p.843−851
- Menegaux F., Olshan A., Reitnauer P., at al. Positive association between congenital anomalies and risk of neuroblastoma// Pediatric Blood & Cancer -2005.- vol.45No 5. P. 649−565.
- Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. //D Cancer Invest. -2007. vol.25, No 1. — P.67−77.
- Munzer С, Menegaux F, Lacour В, Valteau-Couanet D, et al Birth-related characteristics, congenital malformation, maternal reproductive history and neuroblastoma: the ESCALE study (SFCE).// J Cancer. 2008 vol. 122 No 10 .-P.2315−2321.
- Musarella MA, Chan HS, DeBoer G, Gallie BL. Ocular involvement in neuroblastoma: prognostic implications. // Ophthalmology -1984.- vol.91. -P.936−940.
- Narod SA, Hawkins MM, Robertson CM, et al. Congenital anomalies and childhood cancer in Great Britain. //Am J Hum Genet -1997.-Vol. 60. -P. 474 485.
- National Cancer Institute of Canada/.www://NCIC.cancer.ca
- National Cancer Institute http://www.cancer.gOv/c
- Nishihira H, Toyoda Y, Tanaka Y, et al.: Natural course of neuroblastoma detected by mass screening: a 5-year prospective study at a single institution// J Clin Oncol -2000.- Vol. 18, Nol6. P. 3012−3017.
- Norris MD, Borlan SB, Marshall GU, et al. Expression of the gene for multidrug resistance associated protein and outcome in patients with neuroblastoma. // N Engl J Med -1996.- Vol. 334. -P. 231−238.
- Ohali A, Avigad S, Ash S, et al. Telomere length is a prognostic factor in neuroblastoma.//Cancer 2006. — Vol.107, No6. — P. 1391−1399.
- Olshan, AF, Bunin, GR Epidemiology of Neuroblastoma. In: Brodeur, GM, Sawada, T, Tsuchida, Y, Voute, PA eds., Neuroblastoma,// Elsevier -2000.- P. 3339.
- Olshan AF, et al. Hormone and Fertility Drug Use and the Risk of Neuroblastoma: A Report from the Children’s Cancer Group and the Pediatric Oncology Group. //Am J Epidemiol -1999.- Vol. 150.-P.930−938.
- Park J., Eggert A. Neuroblastoma: Biology, Prognosis, and Treatment// Ped Clin -2008.- № 55. P. 97−120
- Parker L, Craft AW, Dale G, et al. Screening for neuroblastoma in the north of England. // British Medical Journal -1992.- Vol. 305, No 6864. -P. 1260−1263.
- Parkin DM, Kramarova E, Draper GJ, Masuyer E, Michaelis J, Neglia J, Qureshi S, Stiller C. International incidence of childhood cancer// IARC Scientific Publication Lyon 1998.- vol II, No 144.
- Pearson A. D. J. et aL High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol.- 2008.- Vol. 9. P. 247−256.
- Perri P., Longo L at al. Linkage analysis in families with recurrent neuroblastoma// Ann NY Acad See -2002.- Vol. 963. -P. 74−84
- Poremba С, Hero B, Goertz HG, et al. Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly.// Klin Padiatr -2001.- Vol. 213, No4. -p. 186−190.
- Quinn JJ, Altman AJ. The multiple hematologic manifestations of neuroblastoma// Am J Pediatr Hematol Oncol -1979.- Vol. 1. -P. 201−205.
- Reynolds C.P. Ras and Seppuku in neuroblastoma. //J Natl Cancer Inst -2002.- Vol. 94, No5. -P. 319−321.
- Riley RD, Heney D, Jones DR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma.// Clin Cancer Res -2004. vol. 10 (1 Pt 1).-P. 4−12
- Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children’s Cancer Group Study. //Med Pediatr Oncol 2001. vol.36 No 6 -P.612−622.
- Sawada T. Past and future of neuroblastoma screening in Japan. //Am J Pediatr Hematol Oncol -1992.- vol.14 No4, P320−326.
- Schell M., Bergeron C. Neuroblastoma.. Orphanet. Encyclopedia 2003. -http: //www.orph.net/data/patho/GB/ukneuroblastoma.pdf
- Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age.// New England Journal of Medicine -2002. vol. 346, Nol4. — P. 10 471 053.
- Schilling FH, Erttmann R, Ambros PF, et al. Neuroblastoma with unfavourable prognostic parameters detected by mass screening: report of the German pilot study. // Proceedings of the American Society of Clinical Oncology -1994.-vol.13 (A-1440). P. 421.
- Schilling FH, Berthold F, Erttmann R, et al.: Population-based and controlled study to evalute neuroblastoma screening at one year of age in Germany: interim results. // Medical and Pediatric Oncology -2000. vol.35, No6. -P. 701−704.
- Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children’s Cancer Group study. //J Clin Oncol -2000.-vol.18, No 6.-P.1260−1268.
- Schmidt ML, Lai A, Seeger RC, Maris JM, Shimada H, et al Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children’s Cancer Group Study. J Clin Oncol -2005. vol.23, No 27. — P. 6474−6480.
- Schneiderman J, London WB, Brodeur GM, Castleberry RP, et al. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children’s Oncology Group.// J Clin Oncol. -2008. vol. 26, No6. -P.913−918.
- Schuz J., Kaletsch U, Meinert R., at al. Risk factors for neuroblastoma at different stages of disease. Results from a population-based case-control study in Germany .// J. of Clinical Epidemiology -2001. vol.54. — P. 702−709.
- Scriver CR, Gregory D, Bernstein M, et al. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec.// CMAJ -1987.-vol. 136, No 9.-P. 952−956.
- Seeger RC, Reynolds CP, Gallego R, et al. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children’s Cancer Group Study. //J Clin Oncol -2000. vol. 18, No24. — P. 40 674 076.
- Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). // Cancer -1999. vol.86, No 2. -P. 364−372.
- Shojaei-Brosseau T, Chompret A, Abel A, et al. Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France.//
- Pediatr Blood Cancer -2004. vol.42. — P. 99−105.
- Shuster JJ, McWilliams NB, Castleberry R, et al. Serum lactate dehydrogenase in childhood neuroblastoma: a Pediatric Oncology Group recursive partitioning study.// American Journal of Clinical Oncology -1992. vol.15, No4. -P. 295−303.
- Simon Т., Spitz R, Hero B. et al. Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes lp and llq. // Cancer Letters. 2005.-P. 1−8. «
- Simon T. Neuroblastoma // Urologe A. -2005. vol.44, No 5. P.543−555.
- Smith EI, Castleberry RP. Neuroblastoma. In: Wells SA Jr, editor. Current problems in pediatric surgery. // Vol. St. Louis: CV Mosby. 1990. — vol. 27, P. 577−620.
- SpitzR, Hero B, SimonT, et al. Loss in chromosome llq identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.// Clin Cancer Res -2006. vol. 12, No 11, Pt 1. — P. 3368−3373.
- Steliarova-Foucher E., Lacour B. et al. International Classification of Childhood Cancer, 3 rd Ed.// Cancer (Philad.) -2005.-Vol. 103. -P. 1457−1467.
- Stiller CA and Parkin DM. International variations in the incidence of neuroblastoma. 11 Int J Cancer -1992/ vol.52. — P.538−543.
- Strenger V, Kerbl R, Dornbusch HJ, et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. // Pediatr Blood Cancer -2007. vol.48, No5. — P. 504−509.
- Suita S., T. Tajiri, Y. Sera, H. Takamatsu, H. Mizote, et al. Behaviours mediastinal Neuroblastoma// Eur J Pediatr Surg. -2000. vol.10, No 6. — P.353−359.
- Tacashi M., Yoshinori H., Kentaro W. et al. A Case of Neuroblastoma Associated With Opsoclonus-Myoclonus-Ataxia Syndrome// Journal of the Japanese Society of Pediatric Surgeons -2006. vol.42, Nol. P. 28−34.
- Takeda T History and current status of neuroblastoma screening in Japan.// Medical and Pediatric Oncology -1989. vol. 17, No 5. — P. 361−363.
- Takeuchi LA, Hachitanda Y, Woods WG, et al. Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec Project.// Cancer -1995. vol.76, Nol 1. -P.2363−2371.
- Tateishi U, Hasegawa T, Makimoto A, Moriyama N. Adult neuroblastoma: radiologic and clinicopathologic features.// J Comput Assist Tomogr. -2003. -vol.27, No 3.-P. 321−326.
- Tomioka N, Oba S, MOhira, AMisra, et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature// Oncogene -2008. vol.27. — P. 441−449.
- Tonini GP, Boni L, Pession A, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.// Journal of Clinical Oncology -1997. vol.15, No l.-P. 85−93.
- Tuchman M, Fisher EJ, Heisel MA, et al. Feasibility study for neonatal neuroblastoma screening in the United States. // Medical and Pediatric Oncology -1989. vol.17, No 4. — P. 258−264.
- Urayama К. Y., Von Behren J., Reynolds P. Birth Characteristics and Risk of Neuroblastoma in Young Children // American Journal of Epidemiology -2007. -vol. 165, No5. P. 486−495.
- Valentiner U, Valentiner FU, Schumacher U. Expression of CD44 is associated with a metastatic pattern of human neuroblastoma cells in a SCID mouse xenograft model. // Tumour Biol. -2008.- vol.29, No3. P. 152−160.
- Warnat P, Oberthuer A, Fischer M, et al. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. //BMC Cancer-2007.- P. 7−89.
- Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma.// N Engl J Med -2002. vol.346, No 14. — P. 1041−1046.
- Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma. // Lancet -1996. vol. 348, No 9043.-P. 1682−1687.
- Woods WG, Tuchman M, Bernstein ML, et al. Screening for neuroblastoma in North America: 2-year results from the Quebec Project. // American Journal of Pediatric Hematology/Oncology -1992. vol.14, No 4. — P. 312−319.
- Woods W. GScreening for neuroblastoma: In concluding head.// J of Ped/ Hematology/Oncology/ -2003.- vol. 25No 1. P. 3−4.
- Yamamoto K, Hayashi Y, Hanada R, et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. // Journal of Clinical Oncology -1995. vol.13 No8. -P. 2033−2038.
- Yaniv I., Ohali A., Avigad S., Cohen I. J., et al. The clinical relevance of telomerase activity and telomere length in pediatric solid tumors. Journal of
- Clinical Oncology, ASCO Annual Meeting Proceedings. // -2005. vol. 23, No 16S, Part I of II.-P. 8547.
- Yeazel MW, Ross JA, Buckley JD, et al. High birth weight and risk of specific childhood cancers: a report from the Children’s Cancer Group. // J Pediatr -1997.-vol. 131, No5. — P. 671−677.
- НИИ ДОГ — научно-исследовательский институт детской онкологии и гематологии.
- ЗНО — злокачественные новообразования АО административный округ
- ASR (от англ. Age-standardized rates) стандартизованные по возраступоказатели
- SIR (от англ. Standardized Incidence Ratio) стандартизованные отношениязаболеваемости ЛПУ- Лечебно- профилактические учреждения РДКБ -Российская детская клиническая больница ДГБ- Детская городская больница ДКБ- Детская клиническая больница